Immune Design Corp. Receivables Turnover Ratio (IMDZ), from the fourth quarter 2018 to the fourth quarter 2017 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Immune Design Corp.  (IMDZ)
 

Immune Design Accounts Receivables Turnover Ratio from the fourth quarter 2018 to the fourth quarter 2017

Quarterly Results, Trends, Rankings, Statistics


Immune Design Corp.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2018 to a ratio of 3.02, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Immune Design in Dec 31 2018 quarter, has decreased to 121 days, compared to 248 days, in the Sep 30 2018 quarter.

If we take a look into Healthcare sector 450 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2018 from 3622 to 3646.

What is Receivable Turnover Ratio?
What is Immune Design Corp. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMDZ Receivables Turnover Ratio (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter		 (Jun 30 2018)
II. Quarter		 (Mar 31 2018)
I. Quarter		 (Dec 31 2017)
IV. Quarter
Y / Y Receivable Change -81.35 % -71.84 % 21.04 % -41.66 % 2.94 %
Y / Y Revenue Change -1.86 % -10.47 % 3.57 % -90.8 % -76.43 %
Receivable Turnover Ratio (TTM) 3.02 1.47 1.05 1.05 3.28
IMDZ's Total Ranking # 3646 # 3622 # 1277 # 4155 # 2858
Accounts Receivable average collection period days 121 248 347 346 111
Seq. Receivable Change -31.09 % 36.76 % 71.17 % -88.44 % 4.07 %
Seq. Revenue Change 3.03 % -38.81 % 50.1 % 3.71 % -6.01 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 183
Healthcare Sector # 451
Overall Market # 3646

Receivable Turnover Ratio Statistics
High Average Low
7.8 3.92 1.05
(Jun 30 2016)   (Jun 30 2018)





IMDZ Company Profile • Back to IMDZ Efficiency Comparisons • Compare IMDZ Receivables Turnover Ratio to its Competitors

Financial Statements
Immune Design's Accounts Receivable $ 1 Millions Visit IMDZ's Balance sheet
Immune Design's Sales TTM $ 2 Millions Visit IMDZ's Income Statement
Sources of IMDZ's Revenues Visit IMDZ's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IMDZ's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IMDZ's Growth Rates IMDZ's Roa IMDZ's Inventory Turnover Ratio IMDZ's Dividend Comparisons
IMDZ's Profitability Ratios IMDZ's Roi IMDZ's Asset Turnover Ratio IMDZ's Dividend Growth
IMDZ's Valuation Ratios IMDZ's Roe IMDZ's Financial Strength Ratios IMDZ's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2018, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2018 Receivable at quarter ending Dec 31 2018
Intercept Pharmaceuticals inc   8.54 $ 179.804  Millions$ 21.057  Millions
Idexx Laboratories Inc  8.53 $ 2,213.242  Millions$ 259.574  Millions
Prophase Labs Inc   8.51 $ 16.312  Millions$ 1.917  Millions
Nrc Health  8.46 $ 119.686  Millions$ 14.148  Millions
Atricure Inc   8.43 $ 201.630  Millions$ 23.926  Millions
Strongbridge Biopharma plc  8.42 $ 18.027  Millions$ 2.140  Millions
Delcath Systems Inc   8.38 $ 3.407  Millions$ 0.407  Millions
Masimo Corp  8.37 $ 858.289  Millions$ 102.509  Millions
Palvella Therapeutics Inc   8.37 $ 29.101  Millions$ 3.477  Millions
American Renal Associates Holdings Inc   8.37 $ 805.776  Millions$ 96.302  Millions
Clearday Inc   8.30 $ 1.756  Millions$ 0.212  Millions
Henry Schein Inc   8.29 $ 13,201.995  Millions$ 1,592.210  Millions
Angiodynamics Inc   8.13 $ 326.887  Millions$ 40.198  Millions
Star Equity Holdings Inc   8.10 $ 104.180  Millions$ 12.858  Millions
Traws Pharma inc   8.08 $ 1.228  Millions$ 0.152  Millions
Vertex Pharmaceuticals Inc  8.07 $ 3,047.597  Millions$ 377.544  Millions
Encision Inc   8.06 $ 8.756  Millions$ 1.086  Millions
American Bio Medica Corporation  8.02 $ 3.872  Millions$ 0.483  Millions
Gw Pharmaceuticals Plc  8.02 $ 15.399  Millions$ 1.920  Millions
Cerus Corporation  8.01 $ 82.285  Millions$ 10.276  Millions
Quanterix Corporation  7.99 $ 37.632  Millions$ 4.710  Millions
Galmed Pharmaceuticals Ltd   7.98 $ 2.038  Millions$ 0.256  Millions
Heartbeam Inc   7.96 $ 399.472  Millions$ 50.189  Millions
Quidelortho Corp  7.96 $ 522.285  Millions$ 65.620  Millions
Atrion Corporation  7.96 $ 152.448  Millions$ 19.163  Millions
Genomic Health Inc  7.94 $ 394.111  Millions$ 49.658  Millions
Pacific Health Care Organization Inc  7.93 $ 6.797  Millions$ 0.857  Millions
Invacare Holdings Corporation  7.90 $ 972.347  Millions$ 123.030  Millions
Cardax Inc   7.88 $ 1.511  Millions$ 0.192  Millions
Mallinckrodt Plc  7.88 $ 3,215.600  Millions$ 408.000  Millions

Date modified: 2026-06-22T11:02:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.